ADIAL PHARMACEUTICALS I-CW23
NASDAQ:ADILW (7/27/2023, 7:00:00 PM)
0.0009
0 (-57.14%)
Adial Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It focused on the development of a therapeutic agent for the treatment of alcohol use disorder. The company's lead product consists of AD04 which is in clinical stage. Adial Pharmaceuticals Inc. is based in CHARLOTTESVILLE.
ADIAL PHARMACEUTICALS I-CW23
Findings underscore the liver safety of AD04 as compared to placebo in the prior Phase 3 clinical trial...
Received Favorable Feedback from US and EU Regulatory Agencies Advancing Discussions with Potential Strategic Partners Received $4.3 Million in Gross...
CHARLOTTESVILLE, Va., March 01, 2024 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage...
New patent strengthens Adial’s patent portfolio and covers AD04’s unique ability to target the serotonin transporter gene for the potential treatment of...
Expands patent estate covering Adial’s unique molecular genetic approach to diagnosing and potentially treating alcohol and drug dependence...
Highly Experienced Pharma Commercial and Business Development Executive in Addiction Treatment Space Joins Leadership Team While Continuing as Board...
Here you can normally see the latest stock twits on ADILW, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: